Advocacy
![Advocacy](https://omsapaprod.wpenginepowered.com/wp-content/uploads/2021/09/Advocacy-hand-shake.png)
September 15, 2021, APNA signed on to a letter to the FDA expressing concerns about the new Clozapine REMS and its impact on patient care along with recommendations.
September 15, 2021, APNA signed on to a letter to the FDA expressing concerns about the new Clozapine REMS and its impact on patient care along with recommendations.